- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02151110
Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults
October 2, 2018 updated by: MedImmune LLC
A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults
Phase 1 single IV dose study to evaluate safety and tolerability of MEDI4920
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
59
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leeds, United Kingdom, LS2 9LH
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 49 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy as determined by a responsible study physician based on medical evaluation
- Body weight 40 to 100 kg
- Body mass index 19.0 to 30.0 kg/m2
Exclusion Criteria:
- History of allergy or sensitivity to Shellfish or protein based antigens
- previous immunization with KLH
- previous splenectomy
- History of diagnosed or suspected thromboembolic event or coagulation disorder
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
|
Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
|
Experimental: MEDI4920 3 mg
Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
|
Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
|
Experimental: MEDI4920 10 mg
Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
|
Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
|
Experimental: MEDI4920 30 mg
Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
|
Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
|
Experimental: MEDI4920 100 mg
Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
|
Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
|
Experimental: MEDI4920 300 mg
Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
|
Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
|
Experimental: MEDI4920 1000 mg
Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
|
Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
|
Experimental: MEDI4920 3000 mg
Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
|
Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
Time Frame: The start of study drug administration (Day 1) to the follow-up period (Day 113) or early discontinuation visit
|
An adverse event (AE) is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.
A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly or birth defect in the offspring of a participant who received the study drug.
A TEAE is defined as the event with onset after the start of infusion (Day 1) to Day 113 or early discontinuation visit inclusive.
The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0.
|
The start of study drug administration (Day 1) to the follow-up period (Day 113) or early discontinuation visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Plasma Concentration (Cmax) of MEDI4920
Time Frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
|
The maximum observed plasma concentration (Cmax) was estimated based on the plasma concentrations of MEDI4920.
Standard deviation was calculated only if number of participants were more than or equal to 3.
|
Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
|
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI4920
Time Frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
|
The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) was estimated based on the plasma concentrations of MEDI4920.
Standard deviation was calculated only if number of participants were more than or equal to 3.
|
Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
|
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MEDI4920
Time Frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
|
The area under the plasma concentration-time curve from time zero to infinity (AUC 0-inf) was estimated based on the plasma concentrations of MEDI4920.
Standard deviation was calculated only if number of participants were more than or equal to 3.
|
Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
|
Dose-normalized AUC0-inf (AUC0-infinity/D) of MEDI4920
Time Frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
|
The AUC (0-infinity)/D is the area under concentration-time curve extrapolated to infinity postdose normalized by MEDI4920 dose.
The AUC (0-infinity)/D was estimated based on the plasma concentrations of MEDI4920.
Standard deviation was calculated only if number of participants were more than or equal to 3.
|
Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
|
Terminal Elimination Half Life (t1/2) of MEDI4920
Time Frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
|
The terminal elimination half-life (t1/2) was estimated based on the plasma concentrations of MEDI4920.
Standard deviation was calculated only if number of participants were more than or equal to 3.
|
Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
|
Systemic Clearance (CL) of MEDI4920
Time Frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
|
The systemic clearance (CL) was estimated based on the plasma concentrations of MEDI4920.
Standard deviation was calculated only if number of participants were more than or equal to 3.
|
Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
|
Volume of Distribution at Steady-state (Vss) of MEDI4920
Time Frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
|
The volume of distribution at steady-state (Vss) was estimated based on the plasma concentrations of MEDI4920.
Standard deviation was calculated only if number of participants were more than or equal to 3.
|
Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
|
Volume of Distribution Based on Terminal Phase (Vz) of MEDI4920
Time Frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
|
The volume of distribution based on terminal phase (Vz) was estimated based on the plasma concentrations of MEDI4920.
Standard deviation was calculated only if number of participants were more than or equal to 3.
|
Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
|
Percentage of Participants Positive for Anti-drug Antibodies (ADA)
Time Frame: Baseline (pre-infusion on Day 1) and post-baseline Days 15, 29, 57, and 113 or early discontinuation visit, whichever occurred first
|
Plasma samples were collected for assessment of anti-drug antibodies (ADA) against MEDI4920.
The incidence of positive serum antibodies to MEDI4920 are presented.
|
Baseline (pre-infusion on Day 1) and post-baseline Days 15, 29, 57, and 113 or early discontinuation visit, whichever occurred first
|
T-cell Dependent Antibody Response (TDAR) Measured by Anti-keyhole Limpet Hemocyanin Immunoglobulin G (Anti-KLH IgG) Concentration
Time Frame: Day 43
|
The T-cell dependent antibody response (TDAR) assay measures the immune response (ie, antibody production) to an introduced antigen, keyhole limpet hemocyanin (KLH).
The KLH is a potent immunostimulating protein with an extensive history of safe and effective use in vaccine development and immunological research.
TDAR was evaluated by measuring anti-KLH IgG titers at a time point consistent with the expected timing for antibody responses following immunization.
The primary time point for the analysis of the TDAR to KLH was Day 43.
The data was presented for geometric mean ratio (MEDI4920/placebo) estimated from the dose response model.
|
Day 43
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 27, 2014
Primary Completion (Actual)
May 9, 2016
Study Completion (Actual)
May 9, 2016
Study Registration Dates
First Submitted
May 27, 2014
First Submitted That Met QC Criteria
May 29, 2014
First Posted (Estimate)
May 30, 2014
Study Record Updates
Last Update Posted (Actual)
February 15, 2019
Last Update Submitted That Met QC Criteria
October 2, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- D5100C00001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer
-
National Heart, Lung, and Blood Institute (NHLBI)TerminatedHealthy | Healthy Volunteer | HVUnited States
-
BiogenRecruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
Angion Biomedica CorpQuotient SciencesNot yet recruitingHealthy VolunteerUnited States
-
University Hospital, ToursRecruitingNeurophysiological Study of Sensory and Cognitive Processes in Healthy Children and Adults (PROSCEA)Healthy VolunteerFrance
-
BiogenActive, not recruiting
-
TeneoFour Inc.Novotech (Australia) Pty LimitedCompletedHealthy VolunteerAustralia
-
Spero TherapeuticsCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States